Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2466 of 3330
Next
>>
>
61626 to 61650 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Antibody	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
BT-20	TNBC	Basal A	Pertuzumab	0.00008	mg/ml	5903.102	1.0364	1.0578	1.2557
BT-20	TNBC	Basal A	Pertuzumab	0.0004	mg/ml	5903.102	1.0655	1.1036	1.2557
BT-20	TNBC	Basal A	Pertuzumab	0.002	mg/ml	5903.102	0.9583	0.9333	1.2557
BT-20	TNBC	Basal A	Pertuzumab	0.01	mg/ml	5903.102	1.0102	1.0162	1.2557
BT-20	TNBC	Basal A	Pertuzumab	0.05	mg/ml	5903.102	1.0769	1.1215	1.2557
BT-20	TNBC	Basal A	Pertuzumab	0.25	mg/ml	5903.102	0.9578	0.9324	1.2557
BT-20	TNBC	Basal A	Pertuzumab	1.25	mg/ml	5903.102	1.0659	1.1043	1.2557
HBL-100	Unknown	Unknown	Pertuzumab	0.0000032	mg/ml	7429.102	0.9958	0.9965	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.000016	mg/ml	7429.102	1.0384	1.0312	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.00008	mg/ml	7429.102	1.0304	1.0248	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.0004	mg/ml	7429.102	1.0076	1.0062	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.002	mg/ml	7429.102	0.9847	0.9874	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.01	mg/ml	7429.102	0.9676	0.9731	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.05	mg/ml	7429.102	0.9868	0.9892	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	0.25	mg/ml	7429.102	0.9430	0.9523	2.4347
HBL-100	Unknown	Unknown	Pertuzumab	1.25	mg/ml	7429.102	0.9275	0.9391	2.4347
HCC1428	HR+	Luminal	Pertuzumab	0.0000032	mg/ml	7441.102	0.9877	0.9731	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.000016	mg/ml	7441.102	1.0278	1.0610	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.00008	mg/ml	7441.102	0.9909	0.9801	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.0004	mg/ml	7441.102	1.0490	1.1073	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.002	mg/ml	7441.102	0.9564	0.9049	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.01	mg/ml	7441.102	0.9598	0.9122	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.05	mg/ml	7441.102	1.0542	1.1188	0.9144
HCC1428	HR+	Luminal	Pertuzumab	0.25	mg/ml	7441.102	0.9604	0.9135	0.9144
HCC1428	HR+	Luminal	Pertuzumab	1.25	mg/ml	7441.102	0.9571	0.9063	0.9144

|<
<<
Previous
Page 2466 of 3330
Next
>>
>
61626 to 61650 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)